CITIC Securities says since early 2026 China's innovative-dr
文 / 小金
2026-09-10 08:30:04
来源:亚金网
CITIC Securities says since early 2026 China's innovative-drug market has seen rapid domestic volume growth. Interim results from leading innovators show fast revenue expansion driven by new products and biopharma firms are moving into a profitability inflection. Overseas programs are entering Phase III/registration-study stages, and several upcoming international conferences create concentrated data catalysts. The firm highlights three investor priorities: (1) leading internationalized innovators poised for global value realization; (2) top domestic innovators entering a new product-ramp growth phase; (3) pipeline assets with global potential whose internationalization may accelerate value realization. CITIC maintains an Outperform rating on the sector.
